((自动化翻译由路透提供，请见免责声明 ))
10月31日 - ** Madrigal Pharmaceuticals 股价上涨多达 17.4%，达到两个月来的最高点 253.55 美元
** 如果涨势保持，股价将创下自2022年12月以来的最佳表现
** 该公司第三季度唯一的产品--脂肪肝药物Rezdiffra的利润为6220万美元，超过华尔街预期的3420万美元 - LSEG
** 脂肪肝被称为代谢功能障碍相关性脂肪性肝炎(MASH)，约占美国人口的 5%。这种疾病早先被称为非酒精性脂肪性肝炎(NASH)。
** 这是连续第二个季度强劲的上市执行，增强了我们对潜在患者/用药者需求的信心。
** MDGL 能够成功利用其先行者优势和商业经验来创造 NASH 市场机会 - Leerink
** 今年 3 月，Rezdiffra 成为首个获得美国 FDA 批准的 NASH 药物。 (link)
** 年初至今，股价上涨了 8.1%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.